Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNH3PG)

• Drug Name: Etoposide Drug Info
• Synonyms: etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 36462
  ChEBI ID: CHEMBL44657
  CAS Number: CAS 33419-42-0
  TTD Drug ID: D0B7EB
  VARIDT Drug ID: DR00162
  INTEDE Drug ID: DR0669
  ACDINA Drug ID: D00258

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
p53 signaling pathway	2.55	0.00e+0	63/73 (86.3%)	CDKN1A;TNFRSF10B;SESN1;...
Influenza A	1.96	0.00e+0	156/172 (90.7%)	TNFRSF10B;FAS;CXCL10;...
Graft-versus-host disease	1.94	0.00e+0	32/42 (76.19%)	FAS;IL1B;IL1A;...
Viral protein interaction with cytokine and cytokine re...	1.94	2.76e-3	84/100 (84%)	TNFRSF10B;CXCL13;CXCL10;...
Malaria	1.92	2.20e-3	44/50 (88%)	IL1B;MET;CXCL8;...
Metabolism of xenobiotics by cytochrome P450	1.92	3.67e-3	49/77 (63.64%)	GSTM3;CYP3A5;ADH5;...
Oxidative phosphorylation	1.88	6.30e-3	93/133 (69.92%)	ATP6V1D;NDUFB1;SDHD;...
Small cell lung cancer	1.83	1.10e-2	90/92 (97.83%)	CDKN1A;DDB2;GADD45A;...
Pyrimidine metabolism	1.82	1.22e-2	40/56 (71.43%)	NME3;TYMP;ENTPD1;...
NF-kappa B signaling pathway	1.81	1.21e-2	90/104 (86.54%)	BLNK;GADD45A;IL1B;...
Cytokine-cytokine receptor interaction	1.80	1.40e-2	246/295 (83.39%)	TNFRSF10B;GDF15;FAS;...
Collecting duct acid secretion	1.79	1.38e-2	22/27 (81.48%)	CA2;ATP6V1D;ATP6V0E2;...
Epstein-Barr virus infection	1.78	1.53e-2	189/202 (93.56%)	CDKN1A;DDB2;FAS;...
Rheumatoid arthritis	1.73	2.83e-2	78/93 (83.87%)	ATP6V1D;IL1B;CXCL8;...
C-type lectin receptor signaling pathway	1.70	3.90e-2	93/104 (89.42%)	PYCARD;IRF9;IL1B;...
Cytosolic DNA-sensing pathway	1.69	3.72e-2	52/63 (82.54%)	CXCL10;PYCARD;IL1B;...
Thyroid cancer	1.68	4.15e-2	36/37 (97.3%)	CDKN1A;DDB2;GADD45A;...
Basal cell carcinoma	1.67	3.98e-2	41/63 (65.08%)	CDKN1A;DDB2;GADD45A;...
Necroptosis	1.67	4.06e-2	113/159 (71.07%)	TNFRSF10B;FAS;PYCARD;...
Measles	1.67	4.02e-2	133/139 (95.68%)	FAS;MX2;MX1;...
Hepatitis C	1.65	4.57e-2	139/157 (88.54%)	CDKN1A;FAS;CXCL10;...
Herpes simplex virus 1 infection	1.65	4.61e-2	165/498 (33.13%)	FAS;TAP1;BAX;...
Non-alcoholic fatty liver disease	1.64	4.70e-2	126/155 (81.29%)	FAS;BAX;IL1B;...
Transcriptional misregulation in cancer	1.63	4.72e-2	158/192 (82.29%)	CDKN1A;DDB2;DUSP6;...
Toll-like receptor signaling pathway	1.63	4.54e-2	94/104 (90.38%)	CXCL10;IL1B;IRF7;...
Fatty acid degradation	1.63	4.41e-2	40/43 (93.02%)	ADH5;ACADVL;ACAT1;...
Other glycan degradation	1.62	4.45e-2	13/18 (72.22%)	FUCA1;NEU1;HEXA;...
Type I diabetes mellitus	1.62	4.45e-2	38/43 (88.37%)	FAS;IL1B;IL1A;...
Human papillomavirus infection	1.62	4.45e-2	284/331 (85.8%)	CDKN1A;FAS;MX2;...
Fluid shear stress and atherosclerosis	1.61	4.62e-2	123/139 (88.49%)	GSTM3;SDC4;IL1B;...
Nicotine addiction	-1.82	1.08e-2	32/40 (80%)	GABRA3;GRIN2B;CHRNA4;...
Cell cycle	-1.84	1.10e-2	110/124 (88.71%)	SKP2;CCNA1;CHEK2;...
Carbohydrate digestion and absorption	-1.85	1.13e-2	37/47 (78.72%)	GNAT3;CACNA1D;HK2;...
RNA transport	-1.88	8.82e-3	128/186 (68.82%)	GEMIN2;PNN;EIF4EBP1;...
Neutrophil extracellular trap formation	-1.90	1.06e-2	101/189 (53.44%)	PLCG1;VDAC1;GP1BA;...
Oocyte meiosis	-1.96	6.61e-3	90/129 (69.77%)	PRKACB;ITPR3;PPP2R1A;...
mRNA surveillance pathway	-2.00	2.94e-3	71/98 (72.45%)	FIP1L1;PPP2R2B;CPSF6;...
Progesterone-mediated oocyte maturation	-2.21	0.00e+0	75/100 (75%)	CCNA1;ADCY2;INS;...
Spliceosome	-2.53	0.00e+0	101/150 (67.33%)	CHERP;PRPF3;PRPF19;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	3.33uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Fibrocystic breast disease

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A (Parent)	CVCL_0598	Homo sapiens	1.11uM - 10uM	3H, 6H, 12H, 24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Fibroblast

Nasopharyngeal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
FIBRNPC	CVCL_UK07	Homo sapiens	10uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	6.66uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	0.37uM - 10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H	Show ▼